In the first poster presentation, PXL770 was shown to have a beneficial effect on the two key pathways involved in non-alcoholic fatty liver disease (NAFLD), the lipolysis in the adipose tissue and de novo lipogenesis in the liver, through direct activation of adenosine monophosphate-activated protein kinase in a diet-induced obesity non-alcoholic steatohepatitis (DIO-NASH) model.
NAFLD is characterized by hepatic lipid accumulation resulting primarily from AT lipolysis, and de novo lipogenesis, highlighting the key role of AT in the development of NAFLD.
In the second poster presentation, PXL065 Phase 1 results demonstrated that PXL065 was shown to be safe and well-tolerated with no adverse events.
Based on the pharmacokinetic results, modeling predicts that a 15 mg dose of PXL065, a deuterium-stabilized R-stereoisomer of pioglitazone, is expected to yield similar efficacy as 45 mg of the parent drug, pioglitazone (Actos) with an improved side effect profile, including reduced weight gain and fluid retention.
In the poster presentation, PXL770 was shown to have a beneficial effect on the liver and AT metabolism in a DIO-NASH mouse model. After 41 weeks, only DIO-NASH mice with biopsy-confirmed steatosis (score ≥2) and fibrosis (stage ≥1) were included and received orally vehicle (control) or PXL770 35 or 75 mg/kg twice-daily for eight weeks.
The DIO-NASH mouse model showed that DIO-NASH mice compared to normal chow diet mice exhibited characteristics of NASH, including steatohepatitis (NAFLD Activity Score, NAS=7), liver fibrosis (score=2), elevated liver triglycerides (TG, x26) as well as inflammation.
In this model, PXL770 at both doses, increased AMPK activity in the liver (P-AMPK/AMPK, +128%; p
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007